MELANOMA

This early-phase trial tested a new vaccine called WDVAX in 23 people with advanced melanoma that had spread. The vaccine is made from each patient's own killed tumor cells, combined with immune-boosting proteins, and formed into a small tablet. The main goals were to see if the …

This early-stage study tested a new RNA cancer vaccine in 119 people with advanced melanoma. The vaccine was designed to train the immune system to attack four proteins found on melanoma cells. The main goal was to check safety and find the right dose, while also looking for sign…

This study tested a personalized vaccine made from each patient's unique melanoma mutations. The goal was to see if the vaccine is safe and can train the immune system to fight remaining cancer cells. 15 people with advanced melanoma participated, and researchers checked for side…

This study tested whether adding denosumab (a bone-strengthening drug) to standard immunotherapy (pembrolizumab or nivolumab) could help control advanced melanoma that has spread. Twenty-five adults with stage III or IV melanoma that had not been treated with immunotherapy before…

This study tested whether adding vibostolimab to the standard immunotherapy pembrolizumab could better prevent melanoma from returning after surgery. About 1,600 people with high-risk stage II to IV melanoma took part. The goal was to see if the combination extended the time with…

This study tested whether combining two drugs, brentuximab vedotin and pembrolizumab, can shrink tumors in people with advanced melanoma, lung cancer, or head and neck cancer that has spread. The trial included 161 participants whose cancer had not responded to prior treatments. …

This early-phase study tested a new drug called BAT4706 in 28 adults with advanced solid tumors (including melanoma) who had no other good treatment options. The main goal was to check the drug's safety and find the highest safe dose. Researchers also looked at how the drug moves…

This study tested a new treatment called GC101 TIL for people with advanced melanoma that did not respond to standard therapies. The treatment uses a patient's own immune cells, grown in a lab, to fight the cancer. The goal was to check safety and see if tumors shrink. 18 patient…

This study tested a new approach for people with advanced melanoma that can be surgically removed. Participants received a combination of two immunotherapies: one injected directly into the tumor (Tavo) and one given through a vein (nivolumab) before surgery. The goal was to see …

This study tested if a new drug, ABP 206, works similarly to the approved drug OPDIVO for people with advanced melanoma that has been removed by surgery. The trial involved 256 adults and compared how the drugs move through the body, their safety, and their effectiveness. The goa…

This early-phase trial looked at combining a special type of radiation (hypofractionated radiotherapy) with two immunotherapy drugs (MEDI4736 and tremelimumab) for people with advanced melanoma, lung, breast, or pancreatic cancer that had spread. The main goal was to find the saf…

This early-stage study tested a new treatment called VE800 combined with the immunotherapy drug nivolumab in 56 people with advanced or metastatic cancers like melanoma, stomach, and colorectal cancer. The main goal was to see if the combination is safe and whether it can shrink …

This early-phase study tested a custom-made yeast vaccine designed to teach the immune system to recognize and attack leftover cancer cells. Five adults with different solid tumors (like colorectal, breast, or lung cancer) who had already completed curative treatment received the…

This study tested several experimental drug combinations, given before surgery, for people with stage III melanoma that can be removed. The goal was to see if these combinations are safe and work better than current treatments. About 146 adults took part, receiving different comb…

This study tested a new approach for people with advanced melanoma (stage III or IV) that cannot be removed by surgery. Participants received injections of a gene therapy directly into their tumors, plus an oral activator drug, to boost the immune system's ability to fight cancer…

This study tested a combination of three immunotherapy drugs (INCMGA00012, INCAGN02385, and INCAGN02390) in 61 people with advanced solid tumors, including melanoma, that had stopped responding to standard treatments. The goal was to find safe doses and see if the drugs could shr…

This study tested an experimental drug (BMS-986253) combined with standard immunotherapy drugs (nivolumab and ipilimumab) in 281 people with advanced cancers like melanoma. The main goals were to check safety and see if the combination could shrink tumors. This is a disease contr…

This study tested experimental treatments for melanoma that has spread to the brain. It involved 56 adults with stage IV melanoma and brain metastases who were not on steroids. The goal was to see if adding new drugs to pembrolizumab (an immunotherapy) is safe and works better th…

This study looked at 216 people with advanced melanoma that didn't respond to standard therapy. Researchers tested each person's tumor for genetic changes and then gave them a drug designed to target those specific changes. The goal was to see if this personalized approach could …

This early-stage study tested an experimental drug called CTX-471, given alone or with another immunotherapy (pembrolizumab), in 100 adults with advanced solid tumors that had stopped responding to standard PD-1/PD-L1 inhibitors. The main goal was to check safety and find the rig…

This early-phase study tested a combination of two drugs, trametinib and ceritinib, in 27 people with advanced melanoma that had stopped responding to standard treatments. The main goals were to find the safest dose and see if the combination could shrink tumors. The study is com…

This study tested a new drug called E7386 combined with the immunotherapy pembrolizumab (and sometimes lenvatinib) in 89 people with advanced melanoma, colorectal cancer, or liver cancer that had stopped responding to prior treatments. The goal was to check safety and find the ri…

This early-stage trial tested a new treatment for people with bladder, skin, or head and neck cancers that have a specific marker called MAGE-A10. Doctors took patients' own immune cells, modified them in a lab to better attack cancer, and gave them back after a short course of c…

This study tested whether a combination of two targeted drugs (dabrafenib and trametinib) could keep melanoma from coming back after surgery in people with high-risk, BRAF-mutated skin cancer. About 870 patients took either the drug combo or placebos for 12 months. The main goal …

This study tested whether a combination of two targeted drugs (LGX818 and MEK162) works better than single drugs for people with advanced melanoma that has a BRAF V600 mutation. About 900 patients took part. The combination helped delay cancer growth longer than the single drugs.…

This early-stage study tested a new drug called CFT1946 in 89 adults with advanced solid tumors that have a specific BRAF V600 gene change. The goal was to find safe doses and see if the drug, given alone or with other medicines, can shrink tumors. The study focused on safety and…

This study tested an experimental drug called PLX3397 in 6 people with advanced melanoma that has a specific change in the KIT gene. The goal was to see if the drug is safe and can shrink tumors. While some patients had their tumors shrink or stay stable, the study was very small…

This study tested a new type of stem cell transplant for children and young adults (ages 2-21) with cancers that came back or didn't respond to treatment. The approach uses a special cell filter to speed up immune recovery after transplant. The main goal was to see if the procedu…

This study tested a new drug called RO7247669 in 93 people with advanced melanoma that could not be removed by surgery or had spread. The goal was to see if the drug could shrink tumors or slow the disease. Participants received one of two dose levels to find the best dose for fu…

This study tested a treatment called lerapolturev, a modified polio virus, alone or with another immunotherapy drug, in 27 adults with advanced melanoma that no longer responded to PD-1 inhibitors. The goal was to see if the virus could shrink tumors or improve outcomes. Particip…

This study tested a new drug combination for people with advanced melanoma that had stopped responding to standard immunotherapy. The treatment involved injecting BO-112 directly into tumors along with pembrolizumab given through a vein. The goal was to see if the combination cou…

This early-phase study tested whether adding a TNF-blocking drug (infliximab or certolizumab) to standard immunotherapy (nivolumab and ipilimumab) is safe for people with advanced melanoma. 33 adults with metastatic or unresectable melanoma participated. The main goal was to find…

This study tested whether a simple, non-invasive breath test can predict if cancer patients will benefit from immunotherapy drugs. Researchers analyzed the breath of 190 adults with lung, melanoma, bladder, kidney, or head and neck cancers to see if unique chemical patterns could…

This study tested whether an artificial intelligence (AI) system could accurately identify melanoma (a dangerous skin cancer) from photos of skin spots. 105 adults with suspicious moles participated. The AI's results were compared to diagnoses from expert doctors and lab tests. T…

This study tested whether a new blood test (liquid biopsy) can accurately find cancer biomarkers in patients with head and neck, lung, or skin cancer. 135 adults with advanced cancer provided blood and tumor tissue samples. The goal was to see if the blood test works as well as t…

This study tested a sun protection program for high school students in rural Utah. The program included in-class lessons and was designed to be easy for schools to continue on their own. Researchers surveyed 38 students before and one month after the program to see if they improv…

This study looked at whether smelling lavender essential oil for 15 minutes before surgery could reduce anxiety in people having skin cancer removed. 66 adults took part, and researchers measured their anxiety levels using questionnaires and vital signs. The goal was to see if th…

This study looked at immune cells (T cells, NK cells, and macrophages) inside melanoma tumors from 217 patients. The goal was to understand how these cells affect the body's ability to fight the cancer or suppress the immune response. Researchers also examined how chemotherapy mi…

This study looked at whether giving a written sheet of advice, in addition to standard verbal counseling, helps first-degree relatives of melanoma patients get a skin exam from a doctor. The study involved 420 participants and aimed to see if the written reminder improves screeni…

This study tested a new method called the mass response biomarker to see if it can predict how well a cancer patient will respond to specific treatments. Researchers collected tumor cells from 72 adults with various cancers using fluid samples or tissue biopsies. The goal was to …

This study examined blood and tumor samples from 25 people with advanced melanoma to understand why some respond to the immunotherapy drug pembrolizumab while others do not. Researchers focused on T cells, a type of immune cell, to find genetic clues that could predict treatment …

This study observed 39 patients in Turkey who had high-risk stage III melanoma removed by surgery and were then treated with dabrafenib and trametinib. Researchers tracked how long patients stayed cancer-free and how long they took the medication. The goal was to see how well the…

This completed study involved 116 people with advanced melanoma. Researchers created a platform to deeply analyze tumor samples, blood, and stool. The goal was to learn more about each person's unique cancer biology and find new molecular patterns that could help guide future tre…

This study checked whether healthy-looking tissue near a melanoma tumor contains hidden, inactive cancer cells that might cause the cancer to come back. Researchers followed 226 people with early-stage melanoma for five years to see if those hidden cells were linked to survival o…

This study looked at 5 people with advanced melanoma to find markers that show if immunotherapy is working. Researchers used special PET scans and took blood and tumor samples before and during treatment with drugs like nivolumab or pembrolizumab. The goal was to see if changes i…

This study looked at 100 adults with stage III melanoma that could be removed by surgery. Researchers compared two drug combinations given before surgery: nivolumab+relatlimab and nivolumab+ipilimumab. The goal was to understand patient characteristics, treatment patterns, and ou…

This study tested whether a family history app can help doctors collect and use information about your family's health to make better decisions. Over 600 adults aged 30-69 took part. The goal was to see if the app increases the number of patients with family history recorded in t…

This study followed 187 adults with melanoma who were treated with IMLYGIC, a virus-based therapy. Researchers wanted to see if the virus spreads to patients' close contacts or healthcare providers, and to check for long-term side effects over 5 years. The goal was to better unde…

This study involved 60 people with advanced melanoma who were already scheduled to receive immunotherapy drugs (either a single drug or a combination). Researchers collected blood samples before and during treatment, and tumor samples when possible, to look for markers that might…

This study looked at how people with a close family member who had melanoma make choices about sun protection. Researchers interviewed 94 participants to understand what influences their use of sunscreen, hats, shade, and protective clothing. The goal is to use these insights to …

This study looked at whether a blood test for circulating tumor DNA (ctDNA) can help predict if melanoma will come back or get worse. Researchers followed 113 adults with melanoma and checked their ctDNA levels alongside standard tests. The goal was to see if ctDNA could be a use…

This study looked at how the body's immune system reacts during cancer treatment with drugs called immune checkpoint inhibitors. Researchers measured inflammatory proteins in the blood of 98 adults with cancers like melanoma and lung cancer. The goal was to find patterns that cou…

This study looked at people with advanced solid tumors (like lung, bladder, or skin cancer) who had been on immunotherapy (PD-1/PD-L1 inhibitors) for one year and whose disease was stable. It randomly assigned them to either stop treatment or continue until their cancer got worse…